Síguenos en Twitter     Síguenos en Facebook     Síguenos en Google+     Síguenos en YouTube     Siguenos en Linkedin     Correo Grupsagessa     Gmail     Yahoo Mail     Dropbox     Instagram     Pinterest     Slack     Google Drive     Reddit     StumbleUpon     Print

SOBRE EL AUTOR **

Mi foto
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com

WORLD EMERGENCY MEDICINE SOCIETIES

Emergency Suprapubic Catheter Placement

Buscar en contenido

Contenido:

domingo, 31 de diciembre de 2017

Giapreza

PulmCCM
PulmCCM - December 22, 2017
"The FDA approved angiotensin-II (Giapreza) as a new intravenous vasopressor for septic shock and other forms of distributive shock. The first new FDA-approved vasopressor in decades, angiotensin-II could significantly change the management of severe septic shock.
FDA based its expedited approval (under priority review) on the ATHOS-3 trial enrolling 321 patients with shock refractory to catecholamines like norepinephrine or epinephrine. At 3 hours, almost 70% of patients with angiotensin II added reached the target blood pressure, compared to 23% receiving placebo and usual vasopressors. The study was not designed to detect a mortality benefit from angiotensin II.
Patients receiving angiotensin II also required lower doses of other vasopressors. The general strategy in the study was to wean off vasopressin first, then catecholamines, while titrating up angiotensin-II.
Angiotensin II patients experienced more thromboses, and FDA advised “Giapreza can cause dangerous blood clots with serious consequences (clots in arteries and veins, including deep venous thrombosis); prophylactic treatment for blood clots should be used.” Similar language will be on the product's label..."